Alex Ovadia to lead Check-Cap for FDA Approval
27 February, 2018
Check-Cap's C-Scan is the first capsule-based system for preparation-free colorectal cancer screening. It is utilizing an innovative ultra-low dose X-ray and wireless communication technologies
Sometimes a different business phase demands different management skills. Check-Cap from Isphiya on mount Carmel, Israel, is facing now this dillema: It is a medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, called C-Scan. But now it enters a new phase aimed at receiving FDA approval and the beginning of commercialization. Techtime has learned that this new phase made the board of directors to change its management.
The company announced the appointment of Alex Ovadia as Chief Executive Officer effective immediately. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition. Prior to this appointment, Ovadia served as Check-Cap’s Chief Operating Officer, Vice President of Research and Development and Israeli site manager since 2013. Ovadia brings more than 25 years of experience leading global operations. He managed complex projects at Philips Healthcare – CT Systems and served in management positions at Elbit Systems.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, “We believe that Alex’s leadership capabilities will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE Mark approval (in January 2018) a key validation of our breakthrough product, we look forward to generate an alternative for colorectal cancer screening.”
Check-Cap’s C-Scan is the first capsule-based system for preparation-free colorectal cancer screening. It is utilizing innovative ultra-low dose X-ray and wireless communication technologies. The capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.